Lantern Pharma Secures FDA IND for Pediatric Cancer Drug, Reports Strong LP-184 Phase 1a Data
LTRN is trading near its 52-week low of $1.11 (11% above the low) on elevated volume (15× avg).
Summary
Lantern Pharma announced significant clinical and regulatory advancements, including FDA IND clearance for STAR-001 through its Starlight Therapeutics subsidiary for a planned Phase 1 pediatric CNS cancer trial. The company also reported the successful completion of its LP-184 Phase 1a trial, achieving all primary endpoints with a 48% clinical benefit rate, and provided updates on LP-300 Phase 2 progress, including a Type C meeting package submission to the FDA. Additionally, LP-284 received FDA Orphan Drug Designation for soft tissue sarcomas, and the company introduced a new AI platform, withZeta.ai, with active beta testing and commercialization potential. These multiple positive milestones across its pipeline and AI platforms provide strong validation for Lantern Pharma's strategy and de-risk several programs, setting the stage for future value-creation catalysts. Investors will be watching for the outcome of the FDA Type C meeting for LP-300 and the initiation of planned Phase 1b/2 trials for LP-184.
At the time of this announcement, LTRN was trading at $1.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.8M. The 52-week trading range was $1.11 to $5.74. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.